lomardexamfetamine

KP106 (lomardexamfetamine) is a novel **prodrug comprised of d-amphetamine and a ligand** developed for the treatment of **Attention Deficit/Hyperactivity Disorder (ADHD)**[1][7][13]. It is intended to be administered as a **proprietary oral film dosage form** leveraging PharmFilm drug delivery technology[3][5][15]. KP106 is designed to release d-amphetamine in a controlled manner, which preclinical and Phase 1 data suggest may result in improved pharmacokinetics, reduced side effects (such as weight loss and cardiovascular effects), and potentially **decreased risk of abuse** compared to existing amphetamine-based therapies (e.g., Vyvanse)[1][3][7][13]. The drug is created using KemPharm's Ligand Activated Therapy (LAT) platform.

Brand names

KP106KP-106KP 106

Other names

KP106KP-106KP 106lomardexamfetamine